remibrutinib
novartis
['remibrutinib', '#1113']
d rner et al. remibrutinib (btki) in pss. + study in pss! improved essdai (disease activity), no effect esspri (pro), trend to improve salivary flow, + effect on multiple labs. #acr22 abstr#1113 
Rheumatologist @stjamesdublin , Associate Professor @tcddublin , Acute Medicine, Vasculitis, ILD, Retired @Emeunet Executive Committee member, @rheum_covid CASC